Skip to main content
TipRanks
Go Ultimate75% OFF

Immuno-Biological Laboratories Co., Ltd. (4570) AI Stock Analysis

0 Followers
JP:4570

Immuno-Biological Laboratories Co., Ltd.

(TSE/TYO:4570)

Select Model
Rating:78Outperform
Price Target:JPY 969.00â–²(14.00% Upside)
Action:reiterated
Date:09/08/26

The company's excellent financial turnaround and fortress-like balance sheet are the primary drivers of the score. This is tempered by a mixed technical picture, where short-term momentum is positive but the stock remains in a longer-term downtrend, and a valuation that is not particularly cheap.

Positive Factors
High-margin profitabilityThe latest period shows strong profitability across gross, operating, and net measures, indicating the reagent and life-science product portfolio can generate substantial value from sales. If these margins persist, they should support reinvestment, resilience, and stronger earnings capacity over the next several quarters.
Negative Factors
Historical earnings volatilityThe sharp swing from substantial losses to strong profits shows that earnings have not yet demonstrated a consistently stable pattern. This history raises the risk that the recent turnaround may be less durable than the latest margins suggest, requiring continued execution to sustain results.

Immuno-Biological Laboratories Co., Ltd. (4570) vs. iShares MSCI Japan ETF (EWJ)

-75%-50%-25%0%25%50%75%100%125%JP:4570-50.34%EWJ+6.46%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 7.92B
Dividend Yield
0.71%
Average Volume (3M)
119.97K
Price to Earnings (P/E)
21.2
Beta (1Y)
1.04
Revenue Growth
7.10%
EPS Growth
17.17%
Country
Japan
Employees
54
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Immuno-Biological Laboratories Co., Ltd. Business Overview & Revenue Model

Company Description

Immuno-Biological Laboratories Co., Ltd. (IBL) is a global entity dedicated to the research, development, production, and distribution of immunological reagents. The company's diverse offerings include ELISA assay kits designed for the precise quanti...

Immuno-Biological Laboratories Co., Ltd. Financial Statement Overview

Summary

Excellent financial health with strong profitability (32.7% net margin), robust cash flow generation, and a very solid balance sheet with minimal debt (9.6% debt-to-equity). The only minor concern is a recent moderation in revenue growth.

Income Statement

85Very Positive

Balance Sheet

92Very Positive

Cash Flow

90Very Positive
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue1.08B1.00B969.53M816.70M794.62M647.58M
Gross Profit777.51M700.28M628.34M517.29M526.71M376.70M
EBITDA368.36M299.82M226.55M128.11M-279.54M-127.50M
Net Income368.32M329.01M249.05M186.69M-289.73M-258.77M
Balance Sheet
Total Assets2.23B2.16B1.85B1.62B1.43B1.71B
Cash, Cash Equivalents and Short-Term Investments907.94M989.47M825.73M734.14M614.16M508.35M
Total Debt171.81M177.09M204.23M235.98M234.99M234.00M
Total Liabilities338.30M311.75M332.03M354.25M355.72M336.99M
Stockholders Equity1.89B1.84B1.51B1.27B1.08B1.37B
Cash Flow
Free Cash Flow0267.68M123.83M115.11M26.46M-93.20M
Operating Cash Flow0301.09M183.50M133.78M26.46M-93.20M
Investing Cash Flow0-116.46M-53.66M-24.50M30.04M-155.63M
Financing Cash Flow0-27.14M-31.75M991.00K991.00K144.00M

Immuno-Biological Laboratories Co., Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price850.00

Price Trends

50DMA1058.70Negative
100DMA1029.23Negative
200DMA1193.44Negative

Market Momentum

MACD-47.86Positive
RSI30.41Neutral
STOCH15.79Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4570, the sentiment is Negative. The current price of 850.00 is below the 20-day moving average (MA) of 961.75, below the 50-day MA of 1058.70, and below the 200-day MA of 1193.44, indicating a bearish trend. The MACD of -47.86 indicates Positive momentum. The RSI at 30.41 is Neutral, neither overbought nor oversold. The STOCH value of 15.79 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4570.

Immuno-Biological Laboratories Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:4570 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:4570JP:457078OutperformJPY 7.92B21.17―0.71%7.10%17.17%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:7776JP:777644NeutralJPY 5.63B-4.61――-49.43%-3.77%
JP:4978JP:497842NeutralJPY 11.22B-24.14――-8.23%-48.10%
JP:7774JP:777442NeutralJPY 25.18B-70.06――17.05%10.47%
JP:4599JP:459939UnderperformJPY 7.65B-4.11―――4.85%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%150%JP:4570JP:4599JP:4978JP:7774JP:7776Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4570 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4570Immuno-Biological Laboratories Co., Ltd.850.00-562.94-39.84%
JP:4599StemRIM Inc.122.00-157.00-56.27%
JP:4978ReproCELL Inc.105.00-50.00-32.26%
JP:7774Japan Tissue Engineering Co., Ltd.620.00134.0027.57%
JP:7776CellSeed Inc.142.00-152.00-51.70%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 08, 2026